RADIAN

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Apr 8, 2019 → Oct 27, 2026

Cited window

Nov 19, 2025 → Oct 25, 2026

Retrieved

Oct 28, 2026

Title

Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Registry

NCT05784012

Study IDs

TTCC-2022-01-RADIAN · 2024-516779-33-00

Sponsor

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Collaborators

GlaxoSmithKline, MFAR

Design

Phase 1/Phase 2 · Interventional, non randomized, parallel

Status

Active, not recruiting

Enrollment

34 actual

Start

2023-11-13 actual

Primary completion

2027-03 estimated

Primary endpoint

1-year disease free survival

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed are not a representative sample of HCP opinion. Multiple closely overlapping posts by one author do not establish consensus or independent confirmation.
• –Discussion using unnamed trial references, alternative wording or transcription variants may be missing. Many sources without explicit trial naming were not read, and one additional X discussion was not fully assessed for clinician views.
• –No full RADIAN protocol or exact-trial results publication was available among the sources reviewed. Historical comparability, statistical uncertainty and detailed safety cannot be independently evaluated here.
• –Exact product-label documents for dostarlimab and cisplatin plus radiotherapy were unavailable; this report draws no regulatory conclusion.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –PRIME comments concern a separate neoadjuvant, surgery-directed study. They cannot establish efficacy, safety or patient-selection rules for RADIAN's definitive-radiotherapy setting.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "RADIAN" (NCT05784012), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "radian-05784012". If you cannot make requests, read https://www.erudio.com/reports/radian-nct05784012.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05784012", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05784012 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/radian-nct05784012.json
curl https://www.erudio.com/reports/radian-nct05784012.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "radian-05784012" })